Related Experiment Video

Updated: Mar 8, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.1K

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies

Alberto Ocana1, Atanasio Pandiella2

  • 1Unidad de Investigación Traslacional, Hospital Universitario de Albacete, Universidad de Castilla La Mancha, Albacete, Spain.

Oncotarget
|January 22, 2017
PubMed

Insights

Triple negative breast cancer (TNBC) remains incurable due to its heterogeneity. This review covers TNBC

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Triple negative breast cancer (TNBC) is a highly heterogeneous and currently incurable malignancy.
  • Significant scientific efforts have been made to understand TNBC's molecular underpinnings.
  • The complexity of TNBC necessitates diverse therapeutic strategies targeting various molecular alterations.

Purpose of the Study:

  • To review the biological basis of triple negative breast cancer.
  • To examine how molecular evidence informs the development of new therapies for TNBC.
  • To highlight ongoing clinical studies and future combination therapy options for TNBC.

Main Methods:

  • Literature review of preclinical and clinical studies on TNBC.
  • Analysis of molecular alterations driving TNBC.
  • Evaluation of current and emerging therapeutic strategies.

Main Results:

  • TNBC's heterogeneity presents a major challenge for treatment.
  • Molecular profiling is crucial for identifying therapeutic targets.
  • Numerous novel therapies are in preclinical and clinical development.

Conclusions:

  • Understanding TNBC's biology is key to developing effective treatments.
  • Targeted therapies and combination strategies show promise for improving outcomes.
  • Continued research into molecular alterations will guide future treatment advancements.
Keywords:
breast cancerkinasesnovel therapiestriple negative breast cancer

More Related Videos

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.0K